Peringatan Keamanan

Severe leukopenia with infection.

Mitoxantrone

DB01204

small molecule approved investigational

Deskripsi

An anthracenedione-derived antineoplastic agent.

Struktur Molekul 2D

Berat 444.4809
Wujud liquid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 75 hours
Volume Distribusi * 1000 L/m2
Klirens (Clearance) * 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2] * 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2] * 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]

Absorpsi

Poorly absorbed following oral administration

Metabolisme

Hepatic

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

673 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Mitoxantrone.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Mitoxantrone.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mitoxantrone.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mitoxantrone.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mitoxantrone.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mitoxantrone.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Mitoxantrone.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mitoxantrone.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mitoxantrone.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mitoxantrone.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Mitoxantrone.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitoxantrone.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mitoxantrone.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Mitoxantrone.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mitoxantrone.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mitoxantrone.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Mitoxantrone.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitoxantrone.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Mitoxantrone.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitoxantrone.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitoxantrone.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitoxantrone.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Mitoxantrone.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitoxantrone.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitoxantrone.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mitoxantrone.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitoxantrone.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mitoxantrone.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Mitoxantrone.
Cladribine Mitoxantrone may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Mitoxantrone.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Mitoxantrone.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Mitoxantrone.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Mitoxantrone.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mitoxantrone.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Mitoxantrone.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Mitoxantrone.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Mitoxantrone.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Mitoxantrone.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Mitoxantrone.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mitoxantrone.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Mitoxantrone.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Mitoxantrone.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Mitoxantrone.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Mitoxantrone.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Mitoxantrone.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Mitoxantrone.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Mitoxantrone.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Mitoxantrone.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Mitoxantrone.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Mitoxantrone.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Mitoxantrone.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mitoxantrone.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mitoxantrone.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mitoxantrone.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Mitoxantrone.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Mitoxantrone.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mitoxantrone.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Mitoxantrone.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Mitoxantrone.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Mitoxantrone.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Mitoxantrone.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Mitoxantrone.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mitoxantrone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mitoxantrone.
Tretinoin The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Mitoxantrone.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Mitoxantrone.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mitoxantrone.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mitoxantrone.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Mitoxantrone.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Mitoxantrone.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Mitoxantrone.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Mitoxantrone.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Mitoxantrone.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Mitoxantrone.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mitoxantrone.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mitoxantrone.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Mitoxantrone.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Mitoxantrone.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mitoxantrone.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Mitoxantrone.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Mitoxantrone.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Mitoxantrone.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Mitoxantrone.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Mitoxantrone.
Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Mitoxantrone.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Mitoxantrone.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mitoxantrone.
Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Mitoxantrone.
Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Mitoxantrone.
Lomustine The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Lomustine.
Dexamethasone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Dexamethasone.
Eculizumab The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Nelarabine.
Abatacept The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Abatacept.
Corticotropin The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Corticotropin.
Cortisone acetate The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Cortisone acetate.
Paramethasone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Paramethasone.
Ciclesonide The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ciclesonide.

Target Protein

DNA topoisomerase 2-beta TOP2B
DNA
DNA topoisomerase 2-alpha TOP2A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 16750460
    Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74.

Contoh Produk & Brand

Produk: 17 • International brands: 0
Produk
  • Mitoxantrone
    Injection, solution • 2 mg/1mL • Intravenous • US • Generic • Approved
  • Mitoxantrone
    Injection, solution • 2 mg/1mL • Intravenous • US • Generic • Approved
  • Mitoxantrone
    Injection, solution • 2 mg/1mL • Intravenous • US • Generic • Approved
  • Mitoxantrone
    Injection, solution, concentrate • 2 mg/1mL • Intravenous • US • Generic • Approved
  • mitoXANTRONE
    Injection, solution, concentrate • 2 mg/1mL • Intravenous • US • Generic • Approved
  • mitoXANTRONE
    Injection, solution, concentrate • 2 mg/1mL • Intravenous • US • Generic • Approved
  • mitoXANTRONE
    Injection, solution, concentrate • 2 mg/1mL • Intravenous • US • Generic • Approved
  • Mitoxantrone
    Injection, solution • 2 mg/1mL • Intravenous • US • Generic • Approved
Menampilkan 8 dari 17 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul